Medicare is making one of its biggest obesity-drug coverage changes in years as demand for GLP-1 medicines continues to grow across the U.S. Starting July 1, 2026, the federal program will open a temporary new pathway for eligible beneficiaries to get certain weight-loss drugs at a fixed monthly cost.
CMS launches a temporary Medicare GLP-1 Bridge on July 1
The Centers for Medicare & Medicaid Services is starting what it calls the Medicare GLP-1 Bridge on July 1, 2026, a short-term demonstration that will give eligible Medicare Part D beneficiaries access to certain GLP-1 drugs through December 31, 2027, according to CMS. CMS said the program will operate outside the usual Part D payment flow and will use a single central processor for prior authorization, claims adjudication and pharmacy payment.
Medicare’s public coverage page says the program will cover Foundayo tablets, Wegovy in injection or tablet form, and Zepbound KwikPen products. Medicare’s fact sheet states that single-dose Zepbound pens and vials are not included. CMS and Medicare.gov also say eligible beneficiaries will pay a flat $50 monthly copay for covered drugs under the program.
That pricing structure comes with an important limitation. CMS said the Part D deductible will not apply to these fills, and the $50 monthly copay will not count toward a beneficiary’s true out-of-pocket spending under Part D. KFF, citing CMS guidance, said the copay also will not count toward the 2026 Part D out-of-pocket cap because the demonstration sits outside the standard Part D benefit.
The program is available nationwide, including all 50 states and U.S. territories, for certain people who already have Medicare drug coverage through a standalone Part D plan, a qualifying Medicare Advantage drug plan, a Special Needs Plan, an employer or union group waiver plan, or the LI NET program, according to Medicare.gov. That means the change is broad geographically, but it does not extend to every person on Medicare.
Eligibility is tied to age, body-mass index and certain medical conditions. Medicare.gov says beneficiaries must be 18 or older and either have a BMI of 35 or more, a BMI of 30 to 34.99 with specified conditions such as uncontrolled hypertension, chronic kidney disease stage 3a or higher, or heart failure with preserved ejection fraction, or a BMI of 27 to 29.99 with conditions including prediabetes, prior heart attack, prior stroke or symptomatic peripheral artery disease.
What remains unsettled for many patients is whether they qualify through the bridge or through traditional Part D coverage for another FDA-approved use. CMS said beneficiaries who already receive GLP-1 coverage through Part D for uses such as type 2 diabetes, sleep apnea or cardiovascular risk reduction would not use the bridge for that same drug. CMS has not released a state-by-state enrollment estimate for the bridge on its public pages.
CMS said the bridge is being run under federal demonstration authority that allows the agency to test payment and reimbursement changes that could improve efficiency and economy in Medicare. KFF reported that the demonstration was extended through the end of 2027 to give CMS more time to collect utilization data and inform future policy decisions tied to broader GLP-1 coverage models.
The policy arrives after years of pressure over obesity treatment access and the high price of blockbuster GLP-1 drugs. Medicare has historically covered these medicines for some non-obesity indications, but not broadly for weight loss alone. CMS’s current approach creates a temporary lane for obesity-focused access while keeping the program administratively separate from the regular Part D benefit.
For beneficiaries, the practical takeaway is straightforward: coverage begins July 1, 2026, only for certain products, only for people who meet the published clinical criteria, and only with provider involvement. Medicare.gov says doctors or other qualified providers must prescribe the drug, complete prior authorization when requested and certify that the medication is being used as part of a lifestyle program focused on diet and exercise. CMS has framed the bridge as a temporary national demonstration, with current authorization running through December 31, 2027.